Trial in patients with AML and “unfit” for chemotherapy, as well as those with Myelodysplastic Syndrome ( MDS), expands potential indications for GMI-1271 and complements planned GlycoMimetics -sponsored registration trial in patients with relapsed/refractory AML Company on track to disclose
ROCKVILLE, Md. --(BUSINESS WIRE)--Dec. 15, 2017-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that it will be included in the NASDAQ Biotechnology Index® (NBI). The annual re-ranking of the NASDAQ Biotechnology Index will be effective prior to market upon on Monday, December 18, 2017 .
Clinical outcomes, including durability of remission and median overall survival, in high-risk patients plus safety and tolerability data presented in oral presentation at American Society of Hematology Annual Meeting and Expo Second oral presentation highlights underlying, differentiated mechanism
ROCKVILLE, Md. --(BUSINESS WIRE)--Nov. 9, 2017-- GlycoMimetics, Inc. (Nasdaq:GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at two healthcare investor conferences next week, as follows: STIFEL 2017 HEALTHCARE CONFERENCE When: November 14, 2017 at 8:00
Ongoing discussions with U.S. Food and Drug Administration ( FDA ) regarding regulatory path for GMI-1271, including planned Phase 3 trial initiation in mid-2018 Pro forma cash balance of $132.1 million as of September 30 Two abstracts accepted as oral presentations at the 2017 American Society of
ROCKVILLE, Md ,--(BUSINESS WIRE)--Nov. 1, 2017-- GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that it will host a conference call and webcast to provide a corporate update and report its third-quarter 2017 financial results on Wednesday, November 8, 2017 , at 8:30 a.m. ET .
GMI-1271 improves efficacy and safety of chemotherapy in Phase 1/2 study in two acute myeloid leukemia (AML) patient populations Preclinical data detail underlying mechanism for GMI-1271’s ability to enhance sensitivity to chemotherapy GlycoMimetics will review the GMI-1271 clinical data during a
ROCKVILLE, MD --(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ:GLYC) today announced that Chief Executive Officer Rachel King will present at BioCentury's Newsmakers in the Biotech Industry Conference. The presentation will take place on Friday, September 8, 2017 at 1:30 p.m.
FDA granted Breakthrough Therapy designation to the Company's drug candidate, GMI-1271, for treatment of adults with relapsed/refractory acute myeloid leukemia (AML) Company completed enrollment in the in Phase 2 portion of its Phase 1/2 trial of GMI-1271 for the treatment of AML Clinicians
ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that the European Patent Office has issued an "intention to grant" letter for European Patent Application Number EP12813711.1, titled "E-Selectin Antagonist Compounds, Compositions, and Methods of Use." This